Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can ...
wrote a new blog entry: 
